Viridian Therapeutics Inc
VRDN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.12B
Close$
$-11.22
147.6% downside
Current Fair Value
147.6% downsideOvervalued by 147.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.12 Billion |
|---|---|
| Enterprise Value | $2.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.32 |
| Beta | 0.9 |
| Outstanding Shares | 107,884,104 |
Return
| Return on Equity | -58.45% |
|---|---|
| Return on Assets | -35.27% |
| Return on Invested Capital | -37.63% |
Valuation & Multiples
| P/E Ratio | -6.68 |
|---|---|
| PEG | -25.51 |
| Price to Sales | - |
| Price to Book Ratio | 3.93 |
| Enterprise Value to Revenue | 30.93 |
| Enterprise Value to EBIT | -5.66 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.37 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.03
Average shareholder expectationRevenue Estimate
$56,364
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.95
Average shareholder expectationRevenue Estimate
$4.04 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 146.19% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.86%▼ 109.08% |
|---|---|
| Total Invested | $16.22M▼ 99.27% |
| Investors Holding | 30▼ 200.00% |
ESG Score
No data
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...